Expert Analysis

Metastatic Breast Cancer

Source: CCO Independent Conference Coverage of the 2006 Annual San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Metastatic Breast Cancer

Faculty:
Clifford A. Hudis, MD George W. Sledge, Jr., MD Debu Tripathy, MD

CME CREDIT INFORMATION

Release Date: 02/27/07

Expiration Date: 02/26/08

Physicians: maximum of 1.75 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.6 contact hours (0.16 CEUs)

Registered Nurses: 1.6 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical trial studies for the treatment of metastatic breast cancer
Describe optimal treatment regimens for treating metastatic breast cancer patients
Define safety profiles associated with treatment regimens for metastatic breast cancer patients

Topics covered include:

Trastuzumab Plus Anastrozole Prolongs PFS in HER2- and Hormone Receptor–Positive Metastatic Breast Cancer
Trastuzumab Plus Bevacizumab in HER2-Positive Recurrent Metastatic Breast Cancer
Capecitabine Added to Trastuzumab/Docetaxel as First-Line Therapy for Metastatic Breast Cancer
Oral Vinorelbine Plus Capecitabine in Metastatic Breast Cancer
Lapatinib Plus Capecitabine Compared With Capecitabine Alone in HER2-Positive Breast Cancer
Weekly Nanoparticle Albumin-Bound Paclitaxel Plus Daily Capecitabine in Metastatic Breast Cancer
Solvent-Free Paclitaxel Compared With Docetaxel in Metastatic Breast Cancer
Albumin-Bound Paclitaxel Plus Bevacizumab in Heavily Pretreated Metastatic Breast Cancer Patients
Hsp90 Inhibitor Tanespimycin (KOS-935) in HER2-Positive Metastatic Breast Cancer
Histone Deacetylase Inhibitor Vorinostat in Metastatic Breast Cancer Patients

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.